Calcium Channel Blockers.. Dieser Artikel ist nicht verfügbar.
Sprache: Englisch
Verlag: Basel, Springer Basel., 2004
- Hardcover
- Gebraucht

Anbieter: Universitätsbuchhandlung Herta Hold GmbH, Berlin, DeutschlandUniversitätsbuchhandlung Herta Hold GmbH
Verkäufer/-in mit 3 Sternen
Verkäufer:in bei ZVAB seit 9. April 2003
Nicht verfügbar
Hardcover
Zustand: Gebraucht
EUR 22,00
Artikelbeschreibung des Verkäufers
2004. 16 x 24 cm. XIV, 262 S. XIV, 262 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. (Milestones in Drug Therapy). Sprache: Englisch.
Bestandsnummer des Verkäufers 389ZB
- Titel
- Calcium Channel Blockers.
- Autor
- Godfraind, Théophile
- Verlag
- Basel, Springer Basel.
- Erscheinungsjahr
- 2004
- Einband
- Hardcover
- Sprache
- Englisch
- ISBN-10
- 3764364351
- ISBN-13
- 9783764364359
- Verkäuferkataloge
- Varia
The drugs named calcium channel blockers (CCBs) were initially termed cal cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2).
„Inhaltsangabe“ gehört möglicherweise zu einer anderen Auflage dieses Titels.